Myeloproliferative disorders.
Murray
Jim
J
University Hospital of Birmingham NHS Foundation Trust, Queen Elizabeth Edgbaston.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D009196:Myeloproliferative Disorders / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D018962:Phlebotomy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013927:Thrombosis / Q000517:prevention & control
D000970:Antineoplastic Agents; D001549:Benzamides; D005343:Fibrinolytic Agents; D010879:Piperazines; D011743:Pyrimidines; D011799:Quinazolines; D000068877:Imatinib Mesylate; C021139:anagrelide; D006918:Hydroxyurea